Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
18741
Transmission electron micrographs of step 5 spermatids.
Published 2017“…<p><b>(A)</b> As the nuclear size (N) of step 5 spermatids decreases, the decondensed chromosomes are aggregated into a retiform pattern. …”
-
18742
-
18743
-
18744
-
18745
vFLIP is not visible in cells expressing RTA.
Published 2014“…<p>vFLIP expression is decreased in 293T cells cotransfected with RTA. 293T cells were transfected with myc tagged vFLIP and RTA where indicated. vFLIP was detected with anti-myc antibody (Millipore) followed by a rhodamine conjugated secondary antibody (Jackson ImmunoResearch). …”
-
18746
A Family of Vanadate Esters of Monoionized and Diionized Aromatic 1,2-Diols: Synthesis, Structure, and Redox Activity
Published 2002“…In solution each ester gives rise to a single <sup>51</sup>V NMR signal (no diastereoisomers), which generally shifts downfield with a decrease in the ester LMCT band energy. …”
-
18747
Heteroplasmy evolution of cybrid clone V_50.
Published 2012“…<p>(A) Average cellular mutation load decreases with increasing passage number of clone V_50. …”
-
18748
-
18749
-
18750
Table 1_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx
Published 2025“…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
-
18751
Table 3_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx
Published 2025“…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
-
18752
Table 2_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx
Published 2025“…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
-
18753
Conservation of superfamilies within five Asgard proteomes.
Published 2021“…This figure was generated using Anvi’o [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0247806#pone.0247806.ref160" target="_blank">160</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0247806#pone.0247806.ref161" target="_blank">161</a>].…”
-
18754
Time courses of HA-GLUT4-eGFP intensity and microtubule density increase.
Published 2012“…(B) Nocodazole pre-treatment decreases the fold change in GLUT4 intensity in response to insulin. …”
-
18755
Social robot PIO (version 3.5).
Published 2025“…The difference between the two groups was statistically significant (<i>t</i> = 3.94, <i>p</i><.001). Depression decreased -0.7±3.48 in the experimental group, from 5.9±4.74 before intervention to 5.2±4.65 after intervention, and decreased by -0.2±3.42, from 6.5±4.69 before intervention to 6.4±4.08 after intervention, in the control group, but the difference between the two groups was not statistically significant (<i>z</i> = -0.59, <i>p</i> =.557). …”
-
18756
The 5hmrC modified mRNAs.
Published 2024“…<p><b>A.</b> Volcano plot of mRNAs that are increased (green) or decreased (red) relative to wildtype levels in <i>Tet</i><sup><i>null</i></sup> LBF preparations; <b>B.…”
-
18757
-
18758
TMD-5 intrinsic Trp fluorescence assay.
Published 2012“…(b), Pentamidine decreases Trp emission fluorescence intensity of TMD-5 in 150 µM C14 betaine and 50 mM HEPES (pH = 7.4) buffer in a dose-dependent manner. …”
-
18759
Inhibition correlates with cellular PmV levels.
Published 2015“…DC6 clone expresses PmV-GFP chimera under regulation of the native promoter [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142509#pone.0142509.ref015" target="_blank">15</a>]; G6 clone, the PmV-GFP-DD chimera under regulation of the native promoter (this paper) and #3 clone (episomally expressing PmV-GFP chimera under <i>Hsp86-5'</i>, a strong and constitutive promoter) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142509#pone.0142509.ref015" target="_blank">15</a>]. …”
-
18760
MCPyV circALTO can be translated.
Published 2021“…<p>(A) CircALTOs do not inhibit MCPyV miRNA function in vitro. 293 cells were transfected with <i>Renilla</i> luciferase reporter with a 300 nucleotide region complementary to the MCPyV miRNA and the indicated plasmids including a MCPyV-miRNA-M1 expression plasmid (derived from isolate MCV350), pCDNA3.1 control vector, pCDNA circALTO1 (pcircALTO1) or pCDNA circALTO2 (pcircALTO2) expression plasmid. …”